The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and XPC on the age at onset of Huntington disease

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 755, Issue 2, 2013, Pages 115-119

  Berger, Frédérique ^a,b   Vaslin, Laurence ^a,b   Belin, Lisa ^a   Asselain, Bernard ^a,b   Forlani, Sylvie ^b,c,d,e   Humbert, Sandrine ^a,c,f   Durr, Alexandra ^c,d,e,g   Hall, Janet ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f INSERM U1005   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Age at onset; Huntington disease; OGG1; XPC

Indexed keywords

7,8 DIHYDRO 8 OXOGUANINE DNA GLYCOSYLASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CAG REPEAT; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE AT ONSET; HUNTINGTON DISEASE; OGG1; XPC;

3' UNTRANSLATED REGIONS; ADULT; AGE OF ONSET; DNA DAMAGE; DNA GLYCOSYLASES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; GUANINE; HAPLOTYPES; HUMANS; HUNTINGTON DISEASE; MALE; MICRORNAS; MIDDLE AGED; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; TRINUCLEOTIDE REPEATS;

EID: 84881023790     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.04.020     Document Type: Article

References (42)

1. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
2. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.
3. Lee J.M., Ramos E.M., Lee J.H., Gillis T., Mysore J.S., Hayden M.R., Warby S.C., Morrison P., Nance M., Ross C.A., Margolis R.L., Squitieri F., Orobello S., Di Donato S., Gomez-Tortosa E., Ayuso C., Suchowersky O., Trent R.J., McCusker E., Novelletto A., Frontali M., Jones R., Ashizawa T., Frank S., Saint-Hilaire M.H., Hersch S.M., Rosas H.D., Lucente D., Harrison M.B., Zanko A., Abramson R.K., Marder K., Sequeiros J., Paulsen J.S., Landwehrmeyer G.B., Myers R.H., MacDonald M.E., Gusella J.F. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012, 78:690-695.
4. Wexler N.S., Res U.V.C. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3498-3503.
5. Hoeijmakers J.H. DNA damage, aging, and cancer. N. Engl. J. Med. 2009, 361:1475-1485.
6. Jeppesen D.K., Bohr V.A., Stevnsner T. DNA repair deficiency in neurodegeneration. Prog. Neurobiol. 2011, 94:166-200.
7. Stack E.C., Matson W.R., Ferrante R.J. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Mitochondria Oxidative Stress Neurodegenerative Disorders 2008, 1147:79-92.
8. Kovtun I.V., Liu Y., Bjoras M., Klungland A., Wilson S.H., McMurray C.T. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 2007, 447:447-452.
9. Grollman A.P., Moriya M. Mutagenesis by 8-oxoguanine - an enemy within. Trends Genet. 1993, 9:246-249.
10. De Luca G., Russo M.T., Degan P., Tiveron C., Zijno A., Meccia E., Ventura I., Mattei E., Nakabeppu Y., Crescenzi M., Pepponi R., Pezzola A., Popoli P., Bignami M. A Role for Oxidized DNA Precursors in Huntington's Disease-Like Striatal Neurodegeneration. PLoS Genet. 2008, 4.
11. Dherin C., Radicella J.P., Dizdaroglu M., Boiteux S. Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1(Ser326Cys) protein which is frequently found in human populations. Nucleic Acids Res. 1999, 27:4001-4007.
12. Hill J.W., Evans M.K. Dimerization and opposite base-dependent catalytic impairment of polymorphic S326COGG1 glycosylase. Nucleic Acids Res. 2006, 34:1620-1632.
13. Kohno T., Shinmura K., Tosaka M., Tani M., Kim S.R., Sugimura H., Nohmi T., Kasai H., Yokota J. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998, 16:3219-3225.
14. Smart D.J., Chipman J.K., Hodges N.J. Activity of OGG1 variants in the repair of pro-oxidant-induced 8-oxo-2'-deoxyguanosine. DNA Repair 2006, 5:1337-1345.
15. Bravard A., Vacher M., Moritz E., Vaslin L., Hall J., Epe B., Radicella J.P. Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res. 2009, 69:3642-3649.
16. Hung R.J., Hall J., Brennan P., Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am. J. Epidemiol. 2005, 162:925-942.
17. Kohno T., Kunitoh H., Toyama K., Yamamoto S., Kuchiba A., Saito D., Yanagitani N., Ishihara S.I., Saito R., Yokota J. Association of the OGG1-Ser326Cys polymorphism with lung adenocarcinoma risk. Cancer Sci. 2006, 97:724-728.
18. Farinati F., Cardin R., Bortolami M., Nitti D., Bass D., de Bernard M., Cassaro M., Sergio A., Rugge M. Oxidative DNA damage in gastric cancer: cagA status and OGG1 gene polymorphism. Int. J. Cancer 2008, 123:51-55.
19. Chen L., Elahi A., Pow-Sang J., Lazarus P., Park J. Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J. Urol. 2003, 170:2471-2474.
20. Elahi A., Zheng Z., Park J., Eyring K., McCaffrey T., Lazarus P. The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 2002, 23:1229-1234.
21. Coppede F., Migheli F., Ceravolo R., Bregant E., Rocchi A., Petrozzi L., Unti E., Lonigro R., Siciliano G., Migliore L. The hOGG1 Ser326Cys polymorphism and Huntington's disease. Toxicology 2010, 278:199-203.
22. Taherzadeh-Fard E., Saft C., Wieczorek S., Epplen J.T., Arning L. Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 2010, 11:435-439.
23. Melis J.P.M., Luijten M., Mullenders L.H.F., van Steeg H. The role of XPC: implications in cancer and oxidative DNA damage. Mutat. Res. Rev. Mutat. 2011, 728:107-117.
24. D'Errico M., Parlanti E., Teson M., de Jesus B.M.B., Degan P., Calcagnile A., Jaruga P., Bjoras M., Crescenzi M., Pedrini A.M., Egly J.M., Zambruno G., Stefanini M., Dizdaroglu M., Dogliotti E. New functions of XPC in the protection of human skin cells from oxidative damage. EMBO J. 2006, 25:4305-4315.
25. Shimizu Y., Iwai S., Hanaoka F., Sugasawa K. Xeroderma pigmentosum group C protein interacts physically and functionally with thymine DNA glycosylase. EMBO J. 2003, 22:164-173.
26. Pecheux C., Mouret J.F., Durr A., Agid Y., Feingold J., Brice A., Dode C., Kaplan J.C. Sequence-analysis of the Ccg polymorphic region adjacent to the Cag triplet repeat of the Hd gene in normal and Hd chromosomes. J. Med. Genet. 1995, 32:399-400.
27. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002, 70:425-434.
28. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 1995, 57:289-300.
29. Sak S.C., Barrett J.H., Paul A.B., Bishop D.T., Kiltie A.E. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidem. Biomar. 2006, 15:2537-2541.
30. Zhu Y.M., Yang H.S., Chen Q., Lin F., Grossman H.B., Dinney C.P., Wu X.F., Gu J. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair 2008, 7:141-148.
31. Kuricova M., Naccarati A., Kumar R., Koskinen M., Sanyal S., Dusinska M., Tulinska J., Vodickova L., Liskova A., Jahnova E., Fuortes L., Haufroid V., Hemminki K., Vodicka P. DNA repair and cyclin D1 polymorphisms and styrene-induced genotoxicity and immunotoxicity. Toxicol. Appl. Pharmacol. 2005, 207:302-309.
32. Vodicka P., Kumar R., Stetina R., Sanyal S., Soucek P., Haufroid V., Dusinska M., Kuricova M., Zamecnikova M., Musak L., Buchancova J., Norppa H., Hirvonen A., Vodickova L., Naccarati A., Matousu Z., Hemminki K. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004, 25:757-763.
33. Qiu L., Wang Z.X., Shi X.Q., Wang Z.Z. Associations between XPC polymorphisms and risk of cancers: a meta-analysis. Eur. J. Cancer 2008, 44:2241-2253.
34. Teo M.T., Landi D., Taylor C.F., Elliott F., Vaslin L., Cox D.G., Hall J., Landi S., Bishop D.T., Kiltie A.E. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 2012, 33:581-586.
35. Mateescu B., Batista L., Cardon M., Gruosso T., de Feraudy Y., Mariani O., Nicolas A., Meyniel J.P., Cottu P., Sastre-Garau X., Mechta-Grigoriou F. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 2011, 17:1627-1635.
36. Berndt S.I., Platz E.A., Fallin M.D., Thuita L.W., Hoffman S.C., Helzlsouer K.J. Genetic variation in the nucleotide excision repair pathway and colorectal cancer risk. Cancer Epidem. Biomar. 2006, 15:2263-2269.
37. Huang W.Y., Berndt S.I., Kang D., Chatterjee N., Chanock S.J., Yeager M., Welch R., Bresalier R.S., Weissfeld J.L., Hayes R.B. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidem. Biomar. 2006, 15:306-311.
38. de Verdier P.J., Sanyal S., Bermejo J.L., Steineck G., Hemminki K., Kumar R. Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat. Res-Fund. Mol. M 2010, 694:39-44.
39. Stern M.C., Lin J., Figueroa J.D., Kelsey K.T., Kiltie A.E., Yuan J.M., Matullo G., Fletcher T., Benhamou S., Taylor J.A., Placidi D., Zhang Z.F., Steineck G., Rothman N., Kogevinas M., Silverman D., Malats N., Chanock S., Wu X.F., Karagas M.R., Andrew A.S., Nelson H.H., Bishop D.T., Sak S.C., Choudhury A., Barrett J.H., Elliot F., Corral R., Joshi A.D., Gago-Dominguez M., Cortessis V.K., Xiang Y.B., Gao Y.T., Vineis P., Sacerdote C., Guarrera S., Polidoro S., Allione A., Gurzau E., Koppova K., Kumar R., Rudnai P., Porru S., Carta A., Campagna M., Arici C., Park S.S.L., Garcia-Closas M., Canc I.C.B. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 2009, 69:6857-6864.
40. Qiao B.L., Ansari A.H., Scott G.B., Sak S.C., Chambers P.A., Elliott F., Teo M.T., Bentley J., Churchman M., Hall J., Taylor C.F., Bishop T.D., Knowles M.A., Kiltie A.E. In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis 2011, 32:516-521.
41. Qiao B.L., Scott G.B., Elliott F., Vaslin L., Bentley J., Hall J., Bishop D.T., Knowles M.A., Kiltie A.E. Functional assays to determine the significance of two common XPC 3' UTR variants found in bladder cancer patients. BMC Med. Genet. 2011, 12.
42. Bradford P.T., Goldstein A.M., Tamura D., Khan S.G., Ueda T., Boyle J., Oh K.S., Imoto K., Inui H., Moriwaki S.I., Emmert S., Pike K.M., Raziuddin A., Plona T.M., DiGiovanna J.J., Tucker M.A., Kraemer K.H. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J. Med. Genet. 2011, 48:168-176.